Literature DB >> 23495745

Biomarker identification for diagnosis of Alzheimer's disease.

Steven Pelech1.   

Abstract

BACKGROUND: Alzheimer's disease (AD) is one of the most pressing and difficult to diagnose unmet diseases confronting industrialized countries. It is characterized by the appearance in the post mortem autopsied AD brain of amyloid plaques containing Aβ42 and paired helical filaments in neurofibrillary tangles with hyperphosphorylated tau.
OBJECTIVE: To investigate the potential of proteomics approaches for AD diagnosis.
METHODS: This reviews focuses on studies of the altered phosphorylation of tau and other proteins as detected in brain biopsy, cerebral spinal fluid (CSF) and blood samples. RESULTS/
CONCLUSION: Detection of decreased Aβ42, and increased total and hyperphosphorylated tau in CSF from AD patients can provide a fairly reliable diagnosis. Furthermore, very recent studies have demonstrated altered levels of cytokines in plasma and differential gene expression and protein phosphorylation in peripheral blood mononuclear cells from AD patients. Identification of the roles of these proteins may provide valuable insights into the underlying molecular pathology of AD and possible sites for therapeutic intervention.

Entities:  

Year:  2008        PMID: 23495745     DOI: 10.1517/17530059.2.5.577

Source DB:  PubMed          Journal:  Expert Opin Med Diagn        ISSN: 1753-0059


  2 in total

1.  Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer's disease.

Authors:  Josef Marksteiner; Christian Humpel
Journal:  Curr Neurovasc Res       Date:  2013-11       Impact factor: 1.990

2.  Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study.

Authors:  Josef Marksteiner; Douglas Imarhiagbe; Michaela Defrancesco; Eberhard A Deisenhammer; Georg Kemmler; Christian Humpel
Journal:  Exp Gerontol       Date:  2013-12-10       Impact factor: 4.032

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.